The ongoing phase II clinical trial ECOG-ACRIN EA5162 (NCT03191149) to prospectively evaluate osimertinib for patients with EGFR exon 20 insertion NSCLC failed to meet its primary endpoint of 30% RR, although preliminary results from 17 evaluable patients demonstrated a RR of 24% and median PFS of 9.6 months [37,38]. Here, EGFR is linked to non-small cell lung carcinoma.